期刊文献+

如何获取与验证生存曲线中生存数据进行Meta分析 被引量:1

Accessibility and validation of survival data in survival curve for meta-analysis
原文传递
导出
摘要 危险比(hazard ratio,HR)作为生存研究的效应指标,是生存资料Meta分析最适宜进行合并分析的效应量,但常因原始研究未直接报道或缺乏而难以获取。目前可采用从原始研究的生存曲线图上截取生存率等数据,并将其与随访时间等信息输入Excel进行转换来获得HR及95%CI的数据。然而,目前国内对相关换算过程的报道较少,且换算的细节未达成一致。本文旨在对如何获取验证生存曲线中的生存数据进行探讨,以期为进行生存数据Meta分析的研究者提供合理的生存数据获取方法。 Hazard ratio (HR) is usually regarded as the effect size in survival studies.Meanwhile,it is supposed to be perfect for pooling results in the meta-analysis of survival data.However,it does not function usually due to absence of original data for pooling HR.As a compromise method,entering data from reading Kaplan-Meier curves and follow-up times into the calculation spreadsheet can also be used to obtain related survival data.But related study on the subject is scarce,and opinions are inconsistent.Accordingly,we conduct this study to further illustrate the procedure in details.
作者 刘清 丁利 LIU Qing;DING Li(Department of General Surgery,Taikang Xianlin Drum Tower Hospital,Nanjing University School of Medicine,Nanjing,210046,P.R.China;Department of Endocrinology,Taikang Xianlin Drum Tower Hospital,Nanjing University School of Medicine,Nanjing,210046,P.R.China)
出处 《中国循证医学杂志》 CSCD 北大核心 2019年第9期1124-1130,共7页 Chinese Journal of Evidence-based Medicine
关键词 生存资料 生存曲线 危险比 META分析 Survival data Survival curve Hazard ratio Meta-analysis
  • 相关文献

参考文献1

二级参考文献10

  • 1罗杰,冷卫东,曾宪涛,等.系统评价Meta分析理论与实践[M].北京:军事医学科学出版社,2013:508-12.
  • 2Higgins JPT,Green S. Cochrane Handbook for Syslematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Coehrane Collaboration, 2011. Available from www.cochrana-hamtbook.org.
  • 3Sterne JAC. Meta-Analysis in Slala: An Updated Collection from the Stata Journal [M]. Stala press,2009.
  • 4Guyot P,Ades AE,Ouwens MJ,et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves[J]. BMC Med Res Methodul,2012,12:9.
  • 5Tierney JF,Stewart LA,Ghersi D,et al. Practical methods for incorporating summary time-to-event data into meta-analysis[J]. Trials,2007,8:16.
  • 6Williamson PR,Smith CT,Hutton JL,et al. Aggregate data meta-analysis with lime-to-event outcomes[J]. Sial Med,2002,21 (22):3337-51.
  • 7Bennouna J,Sastre J Arnold D,et al. Continuation of bevacizumab after first progression in metastatic cnlorectal cancer (MLI8147): a randomised phase 3 trial[J]. Lancet Oncol,2013,14(1):29-37.
  • 8曾宪涛,Joey S.W.Kwong,田国祥,董圣杰.Meta分析系列之二:Meta分析的软件[J].中国循证心血管医学杂志,2012,4(2):89-91. 被引量:92
  • 9董圣杰,冷卫东,田家祥,曾宪涛.Meta分析系列之五:贝叶斯Meta分析与WinBUGS软件[J].中国循证心血管医学杂志,2012,4(5):395-398. 被引量:33
  • 10曾宪涛,田国祥,张超,魏万林.Meta分析系列之十五:Meta分析的进展与思考[J].中国循证心血管医学杂志,2013,5(6):561-563. 被引量:59

共引文献58

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部